Articles by Kenneth I. Kaitin - Pharmaceutical Executive

ADVERTISEMENT

Articles by Kenneth I. Kaitin

Opinion: Memo to von Eschenbach

FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do.
Jan 1, 2006

Often, post-approval marketing studies don't materialize because drug companies question their value. Independent review of the need for such studies would address pharma's concern that they may be warranted.

ADVERTISEMENT

Click here